Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.66 |
| ▸ | CTSS | P25774 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1231627 | 1.00 | CTSK (0.66) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL3450517 | 1.00 | CTSK (0.66) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL17449753 | 1.00 | CTSK (0.66) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL1350139 | 0.90 | CTSK (0.68) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL345582 | 0.90 | CTSK (0.68) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL3448997 | 0.90 | CTSK (0.68) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL3233192 | 0.88 | CTSK (0.62) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL18875931 | 0.88 | CTSK (0.62) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL6037571 | 0.88 | CTSK (0.66) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL14820490 | 0.88 | CTSK (0.62) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137640-A1 | (2S)-2-Aminopentanethioic S-acid for use as medicament and in therapy of amyotrophic lateral sclerosis | MASSEY VENTURES LTD (NZ) | 2026-05-21 | — | — | US | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4255406-B1 | (2S)-2-AMINOPENTANETHIOIC ACID FOR USE AS MEDICAMENT AND IN THERAPY OF AMYOTROPHIC LATERAL SCLEROSIS | MASSEY VENTURES LTD (NZ) | 2026-03-11 | — | — | EP | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250281433-A1 | NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME | AMTIXBIO CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| US-5071848-A | TRICYCLIC QUINOLINE ANTINEOPLASTIC AGENTS | ABBOTT LABORATORIES (US) | 1991-12-10 | — | — | US | disclosed |
| WO-1991016894-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1991-11-14 | — | — | WO | disclosed |
| EP-0424802-A2 | Tricyclic quinoline antineoplastic agents | ABBOTT LABORATORIES (US) | 1991-05-02 | — | — | EP | disclosed |
| US-4994486-A | Neurological disorders | ABBOTT LABORATORIES (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0373497-A2 | Dipeptide derivatives with an enzyme-inhibiting activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-06-20 | — | — | EP | disclosed |
| US-4923965-A | MICROBIOCIDES, FUNGICIDES | POLITECHNIKA GDANSKA (PL) | 1990-05-08 | — | — | US | disclosed |
| US-4302472-A | TREATMENT OF AMEBIASIS | FARMITALIA CARLO ERBA S.P.A. (IT) | 1981-11-24 | — | — | US | disclosed |
| EP-0020481-A4 | ANTIBACTERIAL PEPTIDE. | ABBOTT LAB (US) | 1981-04-24 | — | — | EP | disclosed |
| EP-0020481-A1 | ANTIBACTERIAL PEPTIDE | ABBOTT LABORATORIES (US) | 1981-01-07 | — | — | EP | disclosed |
| WO-1980000789-A1 | ANTIBACTERIAL PEPTIDE | ABBOTT LAB (US) | 1980-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | CTSK 1499/4885CTSS 1265/4885MEN1 3255/4885 |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | CTSK 2864/4885CTSS 1929/4885MEN1 1464/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | CTSK 4661/4885CTSS 4022/4885MEN1 4664/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | CTSK 1659/4885CTSS 1454/4885MEN1 3290/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885MEN1 1667/4885 |
| US-20260137640-A1 | (2S)-2-Aminopentanethioic S-acid for use as medicament and in therapy of amyotrophic lateral sclerosis | SMN1; SMN2, SLC1A2, SLC7A1 | CTSK 1561/4885CTSS 814/4885MEN1 4259/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885MEN1 1667/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | CTSK 1467/4885CTSS 1044/4885MEN1 209/4885 |
| US-20250281433-A1 | NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME | AADAT, AADAC, AHR | CTSK 2601/4885CTSS 1691/4885MEN1 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.